New Issue: Barclays prices $26.46 million 14-month Accelerated Return Notes tied to biotech stocks

By Toni Weeks

San Luis Obispo, Calif., Nov. 26 – Barclays Bank plc priced $26.46 million of 0% Accelerated Return Notes due Jan. 22, 2016 linked to basket of three equally weighted biotechnology sector stocks, according to a 424B2 filing with the Securities and Exchange Commission.

The underlying companies are Biogen Idec Inc., Celgene Corp. and Gilead Sciences, Inc.

The payout at maturity will be par of $10 plus triple any basket gain, up to a maximum return of 20.5%.

Investors will be exposed to any losses.

BofA Merrill Lynch is the agent.

Issuer:	Barclays Bank plc
Issue:	Accelerated Return Notes
Underlying stocks:	Biogen Idec Inc. (Symbol: BIIB), Celgene Corp. (Symbol: CELG) and Gilead Sciences, Inc. (Symbol: GILD), equally weighted
Amount:	$26,461,530
Maturity:	Jan. 22, 2016
Coupon:	0%
Price:	Par
Payout at maturity:	Par plus 300% of any gain in the basket, capped at 20.5%; exposure to any losses
Initial prices:	$305.40 for Biogen, $111.07 for Celgene, $101.11 for Gilead Sciences
Initial basket level:	100
Pricing date:	Nov. 25
Settlement date:	Dec. 3
Underwriter:	BofA Merrill Lynch
Fees:	2%
Cusip:	06742Y477

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.